DANVERS, Mass., June 14, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of break-through heart support technologies, today announced it has received Health Canada approval to market the Impella cVAD device, a new percutaneous Impella® heart pump that provides peak flow of approximately 4 liters of blood per minute.
